ATE273008T1 - Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen - Google Patents

Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen

Info

Publication number
ATE273008T1
ATE273008T1 AT99962960T AT99962960T ATE273008T1 AT E273008 T1 ATE273008 T1 AT E273008T1 AT 99962960 T AT99962960 T AT 99962960T AT 99962960 T AT99962960 T AT 99962960T AT E273008 T1 ATE273008 T1 AT E273008T1
Authority
AT
Austria
Prior art keywords
acid derivatives
nicotinic acid
dna damage
skin cells
treat dna
Prior art date
Application number
AT99962960T
Other languages
English (en)
Inventor
Elaine L Jacobson
Myron K Jacobson
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22333250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE273008(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of ATE273008T1 publication Critical patent/ATE273008T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT99962960T 1998-12-01 1999-12-01 Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen ATE273008T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11048298P 1998-12-01 1998-12-01
PCT/US1999/028446 WO2000032179A2 (en) 1998-12-01 1999-12-01 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells

Publications (1)

Publication Number Publication Date
ATE273008T1 true ATE273008T1 (de) 2004-08-15

Family

ID=22333250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962960T ATE273008T1 (de) 1998-12-01 1999-12-01 Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen

Country Status (15)

Country Link
US (4) US6337065B1 (de)
EP (1) EP1143954B1 (de)
AR (1) AR023715A1 (de)
AT (1) ATE273008T1 (de)
AU (1) AU762770B2 (de)
CA (1) CA2352964C (de)
DE (1) DE69919403T2 (de)
DK (1) DK1143954T3 (de)
ES (1) ES2228146T3 (de)
HK (1) HK1041436B (de)
IL (2) IL143112A0 (de)
NZ (1) NZ511708A (de)
PT (1) PT1143954E (de)
TW (1) TWI257303B (de)
WO (1) WO2000032179A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228146T3 (es) * 1998-12-01 2005-04-01 University Of Kentucky Research Foundation Uso de derivados de acido nicotinico para tratar el daño en el dna de celulas cutaneas.
US20020054895A1 (en) 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US6531500B2 (en) 1999-07-23 2003-03-11 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
US6896897B2 (en) 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
US6864274B2 (en) 1999-07-23 2005-03-08 Alwyn Company, Inc. Allantoin-containing skin cream
US6673826B2 (en) 1999-07-23 2004-01-06 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
JP4156841B2 (ja) * 2000-04-14 2008-09-24 ナイアダイン コーポレーション ナイアシンの経皮送達用局所製剤および高脂血症の処置方法
ATE337784T1 (de) * 2000-04-14 2006-09-15 Niadyne Corp Methoden und zusammensetzung zur verbesserten sauerstoffzufuhr für zellen
US20020182585A1 (en) * 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
ITMI20011019A1 (it) * 2001-05-17 2002-11-17 Carlo Ghisalberti Sostanze furiliche per uso topico
AU2002950744A0 (en) * 2002-08-13 2002-09-12 Medihoney Pty Ltd Composition
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
EP1582207A4 (de) * 2002-12-26 2008-03-05 Ajinomoto Kk Hemmer für ausbruch und progredienz von leberkrebs
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
US20070243570A1 (en) 2003-05-19 2007-10-18 Genecare Research Institute Co., Ltd Apoptosis Inducer for Cancer Cell
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7615641B2 (en) * 2004-07-20 2009-11-10 Sino Pharmaceuticals Corporation Long chain aliphatic alcohol derivatives and methods of making and using same
CN103127111B (zh) 2005-06-24 2016-02-10 代表亚利桑那大学的亚利桑那校董会 用于治疗头发生长病症比如女性型脱发的方法及可用于此的组合物
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008025755A1 (de) * 2006-09-01 2008-03-06 Basf Se Verwendung von n-haltigen heterozyklen in dermokosmetika
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN101742916B (zh) * 2007-02-28 2015-08-19 肯塔基大学研究基金会 减轻视黄酸治疗副作用和/或改进疗效而不干扰疗效的方法
US8815936B2 (en) * 2008-03-03 2014-08-26 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2168574A1 (de) 2008-09-25 2010-03-31 Noureddine Frid Verbindung zur lokalen Tumorentfernung
US8173446B2 (en) 2009-12-21 2012-05-08 General Electric Company Method of producing an integrated micromagnet sensor assembly
US20140135372A1 (en) 2010-02-02 2014-05-15 Elliott Farber Compositions and methods of treatment of inflammatory skin conditions using allantoin
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
CN108026566A (zh) * 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
WO2020089236A1 (en) 2018-11-02 2020-05-07 Unilever Plc Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185679A (en) 1965-05-25 Azepine derivatives
US3276960A (en) 1961-08-21 1966-10-04 Kendall & Co Analgesic methods and compositions
US4246285A (en) 1975-10-20 1981-01-20 The Procter & Gamble Company Skin conditioning compositions containing guanidine inorganic salts
HU184626B (en) 1979-06-01 1984-09-28 Ferrokemia Ipari Congesting cosmetics first of all hair-restorers
EP0057797B1 (de) 1981-02-03 1986-06-25 Imperial Chemical Industries Plc Verfahren zur Extrahierung von Metallwerten und Metallextrahierungsmittel
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US5635497A (en) 1982-06-23 1997-06-03 Yamanouchi Europe B.V. Topical application compositions
US4459153A (en) 1982-09-20 1984-07-10 The United States Of America As Represented By The United States Department Of Energy Pyrochemical process for extracting plutonium from an electrolyte salt
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
ATE82684T1 (de) 1984-03-07 1992-12-15 Roshdy Ismail Mittel zur behandlung und zum schutz der haut.
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
DE3570598D1 (en) 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
DE3532562A1 (de) 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
LU86574A1 (fr) 1986-09-08 1988-04-05 Oreal Composition pour induire et stimuler la croissance des cheveux et freiner leur chute,a base d'esters nicotiniques et de derives de pyrimidine
GB2216003B (en) 1988-02-18 1992-06-10 Toyama Chemical Co Ltd Hair restorer
US4981681A (en) 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
US5133958A (en) 1989-04-20 1992-07-28 Erwin Stuckler Agent for nail, skin and hair care
US5129360A (en) 1990-01-24 1992-07-14 The United States Of America As Represented By The Secretary Of The Air Force Actively cooled effusion cell for chemical vapor deposition
GB9006785D0 (en) 1990-03-27 1990-05-23 Leung Lit Hung Composition and methods for treatment of acne vulgaris and retardation of ageing
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5043162A (en) 1990-09-05 1991-08-27 Trager Seymour F Hair growth promoter
FR2668366B1 (fr) * 1990-10-30 1993-01-29 Oreal Utilisation cosmetique d'une composition ayant une activite antierythemale et composition correspondante.
GB9114346D0 (en) 1991-07-03 1991-08-21 Dow Corning Sa A method of accelerating drug permeation
US5358969A (en) 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5240945A (en) 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US6231852B1 (en) * 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2715565B1 (fr) 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
JP3455544B2 (ja) * 1994-06-02 2003-10-14 リガ ダン 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法
US5612382A (en) 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
DE4433130C2 (de) 1994-09-16 1997-02-06 Deutsches Krebsforsch Poly(ADP-Ribose)-Polymerase überexprimierende tierische Zellinien und Verfahren zur Identifizierung von DNA-schädigenden Substanzen
EP0717984B1 (de) 1994-12-20 2004-11-03 Unilever Plc Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln
US5690944A (en) 1994-12-20 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing lactate dehydrogenase inhibitors
MX9707046A (es) * 1995-03-14 1998-02-28 Deward G Shaskan Composiciones que comprenden nicotinilalanina y un inhibidor de conjugacion de glicina o vitamina b6.
PT823897E (pt) 1995-05-01 2004-11-30 Scarista Ltd Esteres de acido nicotico e composicoes farmaceuticas que os contem
JPH08301760A (ja) * 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
US5571794A (en) 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation
JP3542665B2 (ja) 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
ES2238695T3 (es) * 1995-08-14 2005-09-01 Optigenex, Inc. Composiciones de carotenoide-nicotinamida-zinc y metodos de tratamiento usando las mismas.
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
WO1997026893A1 (en) * 1996-01-24 1997-07-31 Aliatros Medical, A.S. Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid
US5736529A (en) * 1996-03-22 1998-04-07 Neurocal International Inc. Use of NAD-related compounds in the treatment of neural trauma to inhibit neurodegeneration
AUPN892496A0 (en) * 1996-03-25 1996-04-18 Technical Consultancy Services Pty Limited Acne treatment
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
AU3000499A (en) * 1998-03-16 1999-10-11 Procter & Gamble Company, The Method of reducing cellulite in mammalian skin
US6277613B1 (en) 1998-06-10 2001-08-21 The Rockefeller University TRF1 binding protein, methods of use thereof
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
US5976513A (en) 1998-10-16 1999-11-02 The Procter & Gamble Company UV protection compositions
ES2228146T3 (es) * 1998-12-01 2005-04-01 University Of Kentucky Research Foundation Uso de derivados de acido nicotinico para tratar el daño en el dna de celulas cutaneas.

Also Published As

Publication number Publication date
US20040147491A1 (en) 2004-07-29
HK1041436B (zh) 2005-03-11
EP1143954B1 (de) 2004-08-11
DE69919403D1 (de) 2004-09-16
CA2352964C (en) 2006-10-17
IL143112A (en) 2006-10-31
DE69919403T2 (de) 2005-09-08
US6403619B1 (en) 2002-06-11
US6552050B2 (en) 2003-04-22
ES2228146T3 (es) 2005-04-01
TWI257303B (en) 2006-07-01
WO2000032179A3 (en) 2001-12-13
AU762770B2 (en) 2003-07-03
WO2000032179A2 (en) 2000-06-08
US6337065B1 (en) 2002-01-08
IL143112A0 (en) 2002-04-21
AR023715A1 (es) 2002-09-04
HK1041436A1 (en) 2002-07-12
CA2352964A1 (en) 2000-06-08
US20010033848A1 (en) 2001-10-25
DK1143954T3 (da) 2004-12-20
PT1143954E (pt) 2004-12-31
AU1929200A (en) 2000-06-19
US7425319B2 (en) 2008-09-16
EP1143954A2 (de) 2001-10-17
NZ511708A (en) 2003-12-19

Similar Documents

Publication Publication Date Title
ATE273008T1 (de) Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
DE69927969D1 (de) Kontrollierte freisetzung von liponsäure
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69600012T2 (de) Verwendung von Salicylsäure-Derivativen zur Hautbleichung
DE69813935D1 (de) Verwendung von Retinoiden zur Induzierung von Hautpigmentierung
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69719495D1 (de) Verwendung von inhibitoren der retinosäureaktivität zur behandlung empfindlicher haut und/oder durch uv strahlung bewirkter akuter schädigungen
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE259155T1 (de) Verfahren zur verwendung von emamectin zur behandlung von fisch-parasiten
ATE255892T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
ATE302023T1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
DE60020591D1 (de) Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
DE69726054D1 (de) Zellen zur behandlung von demenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1143954

Country of ref document: EP